- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: CNTO-1275 | L04AC05 | Stelara® | TT-20
ustekinumab is an approved drug (FDA (2009), EMA (2009))
Compound class: Antibody
Comment: Ustekinumab suppresses the immunomodulatory actions of both IL-12 and IL-23 on T-cell sub-populations. It binds to the common p40 subunit (IL12B) shared by these cytokines.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Qyuns Therapeutics have a potential ustekinumab biosimilar (QX001S) in Phase 1 evaluation for psoriasis (trial registry number ChiCTR1900022127).
|The patent covering the production and use of ustekinumab (US6902734 ) does not provide affinity values for specific antibody clones, therefore we have included the stated range of affinities determined in the production and testing process in the interaction table below..|
|Selectivity at ligand targets|
|Key to terms and symbols||Click column headers to sort|